Prevalence of influenza and pneumococcal vaccine uptake in Saudi type 2 diabetic individuals

Abstract

Introduction: Individuals with diabetes are at particularly at high risk for many of the negative health consequences associated with influenza and pneumococcal infections. This study aimed to determine the prevalence of influenza and pneumococcal vaccination among a population of type 2 diabetic patients in Saudi Arabia and to determine the factors associated with vaccine uptake. Methods: A cross-sectional survey was conducted among patients with type 2 diabetes at Security Forces Hospital, Riyadh in Saudi Arabia. The survey asked basic demographic questions as well as questions about awareness, vaccination status, and beliefs about the influenza and pneumococcal vaccines. Results: From a total number of 422 responses, 360 participants were ultimately included in the final sample. The overall prevalence of influenza and pneumococcal vaccination in this population were 47.8% and 2.8%, respectively. In general, there was a very low awareness of the pneumococcal vaccine. Older individuals, unmarried individuals, those with less education, and those living with certain chronic conditions were less likely to have gotten the influenza vaccine. Beliefs in the importance of vaccination for people with diabetes, the efficacy of the influenza vaccine, and not being worried about the side effect of the vaccine were strongly associated with having received the vaccine. Conclusions: Attention should be given to increasing awareness of the pneumococcal vaccine among people living with diabetes. Particular consideration should also be paid to increasing access and awareness to both vaccines among those groups that have the lowest prevalence of vaccination and may be at the highest risk for the negative consequences associated with these infections. Finally, education interventions should be used to increase the understanding of the safety and efficacy of the influenza vaccine.

Evaluation of Influenza, Pneumococcus, Zoster, Measles, Diphtheria, and Pertussis Vaccination Rates in Patients with Type 1 and Type 2 Diabetes Mellitus; a Single-Center Experience From Turkey

“…In developing countries, data for uptake of the recommended vaccines in diabetic patients is insufficient. Rates of IV were reported to vary between 0.4% and 28%, and rates of PV varied between 0.7 and 26% (32)(33)(34)(35). The rates of IV and PV in our study were slightly higher compared to the study results from other developing countries, including China, India, Morocco, and Thailand.…”

Association between knowledge of influenza vaccine and vaccination status among general population attending primary health care centers in Al-Madinah, Saudi Arabia

“…[145] The influenza vaccine is considered the most effective strategy for preventing severe illness and complications associated with influenza infection. [67] In Saudi Arabia, the vaccine is provided free of charge in all the PHCs. [7] Literature highlighted potential reasons of vaccine hesitancy: misconceptions that vaccine causes influenza or vaccine is unsafe during pregnancy.…”

“…[67] In Saudi Arabia, the vaccine is provided free of charge in all the PHCs. [7] Literature highlighted potential reasons of vaccine hesitancy: misconceptions that vaccine causes influenza or vaccine is unsafe during pregnancy. [89] Similar misconceptions were prevalent among healthcare workers who were reluctant to receive vaccinations.…”

Utility of pneumococcal vaccine among elderly population in buraidah primary health care centers

“…17 To compare the present study finding, a study was conducted in the family medicine department at security forces hospital in Riyadh, Saudi Arabia found out that 93.9% of participants reported not received the pneumococcal vaccine, 3.3% replied as don't know and 2.8% were received pneumococcal vaccine. 11 In a study of a cross-sectional survey among the Gulf cooperation council (GCC) countries' residents, overall 22% of the participants reported receiving the pneumococcal vaccine in the three years previous to the survey and the remaining 78% reported not receiving the vaccine. The vaccine coverage rate varied broadly across the countries, ranging from 0% in Bahrain 7% in Saudi Arabia to 79% in Kuwait.…”

“…10 PCV23 is made of capsular polysaccharides from 90% of the most common infections a23 serotypes. 11 The PCV23 is given at least once in a life. In immune-competent aging 50 and above should get one dose of PCV13 followed by PPSV23 after 1-year.…”